

DURECT CORP  
Form 8-K  
June 16, 2010

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## Form 8-K

### Current Report

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

June 16, 2010

Date of Report

(Date of earliest event reported)

## DURECT CORPORATION

(Exact name of Registrant as specified in its charter)

Delaware  
(State or other jurisdiction of

000-31615  
(Commission

94-3297098  
(I.R.S. Employer

Edgar Filing: DURECT CORP - Form 8-K

incorporation or organization)

File Number)  
2 Results Way

Identification No.)

Cupertino, CA 95014

(Address of principal executive offices) (Zip code)

(408) 777-1417

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On June 16, 2010, DURECT Corporation, a Delaware corporation (DURECT), issued a press release announcing results from a European Phase IIb hysterectomy clinical trial conducted by Nycomed of POSIDUR (also known as SABER -bupivacaine or Optesia in the E.U.), a proprietary product under development for the treatment of post-surgical pain. Nycomed is DURECT's licensee of commercialization rights to POSIDUR for the E.U. and other selected countries. A copy of DURECT's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

99.1 Press Release of DURECT Corporation dated June 16, 2010

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DURECT Corporation**

Date: June 16, 2010

By: */s/* JAMES E. BROWN  
**James E. Brown**  
**President and Chief Executive Officer**

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release of DURECT Corporation dated June 16, 2010